Thomas G. Perkins1, James B. Murdoch1, Bryan Goss2
1Philips Healthcare, Cleveland, OH, USA; 2New Mexico Cancer Center, Albuquerque, NM, USA
Proton MR Spectroscopy (1H-MRS) has been established for many years as a valuable tool in the study and diagnosis of neurological disorders, in particular for oncological follow-up of post-treatment brain tumors. Recently, 1T spectra were acquired on patients with normal brain chemistry to explore the clinical utility of 1H-MRS on a commercially available high field (1.0T) open MR system. Based on the success of this previous study, a clinical test is underway to evaluate the quality of spectra that can be obtained on patients with brain pathology within an oncology practice. Initial results of this study are presented here.